Business Wire

One Banana Presents Its Sustainability Report 2020

21.7.2021 23:27:00 EEST | Business Wire | Press release

Share

One Banana, the better banana Co., presents its seventh Corporate Sustainability Report reflecting on the achievements and execution of its Sustainability Strategy amid a life-changing year in 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005928/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Amid a life-changing year, One Banana presents its 7th Corporate Sustainability Report reflecting on the achievements made in the execution of its Sustainability Strategy in 2020. With new projects and continuing existing ones, One Banana aims to promote the well-being of customers, workers, their families, and communities through continuous improvement, environmental conservation, education, health and nutrition projects, among others. (Photo: Business Wire)

"We have taken more time, effort, and resources to prepare and publish our sustainability report due to the implementation of new methodologies to better measure and present how we create sustainable value," said Javier Aguirre, Corporate Director of AgroAmerica. "In this challenging year, we updated the pillars of our Corporate Sustainability Strategy to align business priorities and the changing expectations of our stakeholders."

One Banana and One Banana Ingredients are the brands under which AgroAmerica commercializes bananas and natural ingredients. This year, the corporation consolidated the banana ingredients business, reducing waste to a minimum and offering its customers a new range of sustainable food.

Some outstanding achievements are:

  • 186 million bananas transformed into food ingredients under the principle of zero waste.
  • Employment generation for 12,537 direct and indirect positions, promoting gender equality and growth opportunities for employees, their families, and communities.
  • Responsible use of natural resources through investment in technology that allows a reduction of up to 50% in water use compared to traditional irrigation technologies.
  • 11 international certifications, supporting the statement: We strive to achieve sustainable production every day.
  • Unprecedented efforts to address the COVID-19 pandemic and extraordinary response to two hurricanes in the Central American region.
  • Continuity of existing projects regarding environmental conservation, education, health and nutrition, among other projects to promote the well-being of workers, their families, and communities in the area of influence, as well as support for community management activities.

“We are pleased to present our Sustainability Report to our customers, suppliers, certifying entities, and the general public,” said Fernando Bolaños, CEO of AgroAmerica. “It reflects our commitment to do responsible business and align our corporate management with the Sustainable Development Goals while complying with the Communication on Progress (CoP) before the United Nations Global Compact, an entity of which we have been a signatory since 2020.”

This report reaffirms the corporation’s commitment to producing food and ingredients responsibly and sustainably.

"Our report notes the progress we have made and sets our expectations for the future," said Robert Adams, President of One Banana. "allowing One Banana to be the better banana Co.”,

View full report here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Javier Aguirre
Corporate Director
sustainability@agroamerica.com
(502) 2420-9600

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release

Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release

Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release

Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior

European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye